当前位置： SCI文献检索 > INTERNATIONAL JOURNAL OF HEMATOLOGY期刊下所有文献 > Safety, therapeutic effectiveness, and cost of parenteral iron therapy.

Safety, therapeutic effectiveness, and cost of parenteral iron therapy.

Abstract：

:Patients have to discontinue the use of oral iron therapy due to the development of side effects and lack of long-term adherence to medication for iron deficiency anemia. This study aimed to evaluate the therapeutic effectiveness, safety, and cost of intravenous iron sucrose therapy. The computerized database and medical records of 453 patients diagnosed with iron deficiency anemia who received intravenous iron sucrose therapy for iron deficiency anemia between 2004 and 2008 were reviewed. The improvement of hematologic parameters and cost of therapy were evaluated 4 weeks after therapy. 453 patients (443 females, 10 males; age: 44.2 +/- 12.3 years) received iron sucrose therapy. Mean hemoglobin, hematocrit, and mean corpuscular volume values were 8.2 +/- 1.4 g/dL, 26.9 +/- 3.8%, and 66.1 +/- 7.8 fL, respectively, before therapy and 11.5 +/- 1.0 g/dL, 35.8 +/- 2.5%, 76.5 +/- 6.1 fL, respectively, after therapy (P < 0.001). A mean ferritin level of 3.4 +/- 2.4 ng/mL before therapy increased to 65.9 +/- 40.6 ng/mL after therapy (P < 0.001). All patients responded to intravenous iron therapy (transferrin saturation values of the patients were >50%). The mean cost of therapy was 143.07 +/- 29.13 US dollars. The therapy was well tolerated. Although the cost of intravenous iron sucrose therapy may seem high, a lack of adherence to therapy and side effects including gastrointestinal irritation during oral iron therapy were not experienced during intravenous therapy.

journal_name

Int J Hematol

journal_title

International journal of hematology

authors

Asma S,Boga C,Ozdogu H

doi

10.1007/s12185-009-0352-z

subject

Has Abstract

pub_date

2009-07-01 00:00:00

pages

24-27

issue

1

eissn

0925-5710

issn

1865-3774

pii

10.1007/s12185-009-0352-z

journal_volume

90

pub_type

临床试验,杂志文章

相关文献

INTERNATIONAL JOURNAL OF HEMATOLOGY文献大全
  • Frequent expression of human Thy-1 antigen on pre-B cell acute lymphoblastic leukemia with t(9;22).

    abstract：:Thy-1 (CDw90) is a phosphatidylinositol-anchored protein, and is expressed on human pluripotential hematopoietic stem cells. The expression pattern of this antigen on leukemia cells is still controversial. In this study, 72 adult patients with pre-B cell acute lymphoblastic leukemia (pre-B ALL) were examined for the e...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1016/s0925-5710(98)00021-8

    authors： Takahashi T,Mizutani M,Miwa H,Katayama N,Nishii K,Shikami M,Yamaguchi M,Shiku H,Kamada N,Kita K

    更新日期：1998-06-01 00:00:00

  • The effect of cell surface glycosaminoglycans (GAGs) on the inactivation of factor VIIa--tissue factor activity by antithrombin III.

    abstract：:We investigated the effect of cell surface glycosaminoglycans (GAGs) on the inactivation of factor VIIa-tissue factor activity by antithrombin III (ATIII) on a human bladder carcinoma (J82) cell line and an ovarian carcinoma (OC-2008) cell line, two tumor cell lines which constitutively synthesize and express high lev...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1016/s0925-5710(98)00034-6

    authors： Hamamoto T,Kisiel W

    更新日期：1998-07-01 00:00:00

  • Current status of ex vivo gene therapy for hematological disorders: a review of clinical trials in Japan around the world.

    abstract：:Gene therapies are classified into two major categories, namely, in vivo and ex vivo. Clinical trials of human gene therapy began with the ex vivo techniques. Based on the initial successes of gene-therapy clinical trials, these approaches have spread worldwide. The number of gene therapy trials approved worldwide inc...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：10.1007/s12185-016-2030-2

    authors： Tani K

    更新日期：2016-07-01 00:00:00

  • An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma.

    abstract：:We evaluated the efficacy and toxicity of a new salvage regimen, consisting of rituximab (375 mg/m(2), day 1), ifosfamide (1500 mg/m(2) on days 3-7), etoposide (150 mg/m(2), days 3-5), cytarabine (100 mg/m(2), days 3-5) and dexamethasone (40 mg/body, days 3-5) (R-IVAD) for relapsed or refractory aggressive B-cell lymp...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-011-0884-x

    authors： Miura K,Takei K,Kobayashi S,Kiso S,Hirabayashi Y,Hojo A,Kodaira H,Yagi M,Kurita D,Kobayashi Y,Tanaka T,Iriyama N,Hatta Y,Kura Y,Yamazaki T,Sawada U,Takeuchi J

    更新日期：2011-07-01 00:00:00

  • Occurrence of lymphoplasmacytic lymphoma 6 years after amelioration of primary cold agglutinin disease by rituximab therapy.

    abstract：:Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia, classified into primary and secondary types. Secondary CAD accompanies infection or malignant disease, most often lymphoma, whereas primary CAD frequently represents a lymphoproliferative bone marrow disorder characterized by clonal expansion of B ce...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-012-1158-y

    authors： Tanaka H,Hashimoto S,Sugita Y,Sakai S,Takeda Y,Abe D,Takagi T,Nakaseko C

    更新日期：2012-10-01 00:00:00

  • CD34+ progenitor cell transplantation from two HLA-mismatched healthy fathers to two infants with severe aplastic anemia.

    abstract：:Pluripotent stem cells of hematopoiesis are included among CD34+ cells in the blood and bone marrow. After granulocyte-colony stimulating factor (G-CSF) mobilization, 1-2% of the mononuclear cells in the blood are CD34+ cells, which can be obtained by leukapheresis. We performed CD34+ progenitor cell transplantation i...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1016/s0925-5710(97)00088-1

    authors： Yasui M,Park YD,Okamura T,Chayama K,Yoshimoto T,Inoue M,Yagi K,Kawa K

    更新日期：1998-01-01 00:00:00

  • Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.

    abstract：:According to the 2008 WHO classification, the category of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) includes atypical chronic myeloid leukaemia (aCML), chronic myelomonocytic leukaemia (CMML), MDS/MPN-unclassifiable (MDS/MPN-U), juvenile myelomonocytic leukaemia (JMML) and a "provisional" entity, refracto...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：10.1007/s12185-014-1670-3

    authors： Zoi K,Cross NC

    更新日期：2015-03-01 00:00:00

  • Primary plasma cell leukemia followed by testicular plasmacytoma.

    abstract：:Plasma cell leukemia (PCL) is a highly aggressive plasma cell disease characterized by a poor prognosis and a low response rate to conventional therapy. Herein, we describe a 69-year-old patient with primary PCL, developing testicular disease while in complete hematological remission, following by muscle involvement a...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-010-0745-z

    authors： Valentini CG,Bozzoli V,Fianchi L,Voso MT,Di Paolantonio G,Criscuolo M,Leone G,Larocca LM,Pagano L

    更新日期：2011-02-01 00:00:00

  • Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.

    abstract：:Abnormal platelet-derived growth factor receptor (PDGFR)-mediated signaling may cause hematologic neoplasm. The PDGFR beta (PDGFRB) gene, located at chromosome band 5q31-33, forms a fusion gene as a result of chromosome translocation. Although patients with PDGFRB rearrangement mostly present with myeloproliferative n...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-016-2167-z

    authors： Shimomura Y,Maruoka H,Ishikawa T

    更新日期：2017-05-01 00:00:00

  • Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy.

    abstract：:The changes of the FVIII binding capacity of vWF after the infusion of FVIII/vWF concentrate was studied in two patients with type 2N vWD, and also during pregnancy in one of them. After infusion of FVIII or DDAVP to the patients, FVIII:C in plasma increased as expected, but it then decreased, with a markedly short ha...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1016/0925-5710(96)00470-7

    authors： Nishino M,Nishino S,Sugimoto M,Shibata M,Tsuji S,Yoshioka A

    更新日期：1996-08-01 00:00:00

  • A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.

    abstract：:A prospective randomized study was conducted to compare the efficacy and toxicity of two anthracyclines for the treatment of patients with acute myelogenous leukemia (AML). Fifty-eight patients were randomized and received induction therapy consisting of cytosine arabinoside (AraC) 100 mg/m2/day for 7 days combined wi...

    journal_title：International journal of hematology

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Takemoto Y,Sampi K,Kuraishi Y,Okabe K,Tamura K,Mizoguchi H,Saito H,Masaoka T,Ogawa M

    更新日期：1999-07-01 00:00:00

  • Hydroxyurea for hemoglobin E/β-thalassemia: a systematic review and meta-analysis.

    abstract：:Hemoglobin E-beta thalassemia (Hb E/β-thalassemia) is a distinct, yet common, type of β-thalassemia, in which the patient co-inherits a β-thalassemia allele from one parent, and a structural variant, Hb E, from the other parent. This co-inheritance leads to remarkable clinical heterogeneity, varying degrees of chronic...

    journal_title：International journal of hematology

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s12185-017-2307-0

    authors： Algiraigri AH,Kassam A

    更新日期：2017-12-01 00:00:00

  • Severe bleeding tendency caused by leukemic infiltration and destruction of vascular walls in chronic neutrophilic leukemia.

    abstract：:Bleeding is reportedly one of the major causes of death in patients with chronic neutrophilic leukemia (CNL), but thrombocytopenia, abnormal platelet functions, or coagulopathy has been confirmed to be the cause of the bleeding tendency in only a small proportion of the patients. We report the case of a 49-year-old wo...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/BF02982088

    authors： Noguchi T,Ikeda K,Yamamoto K,Ashiba A,Yoshida J,Munemasa M,Takenaka K,Shinagawa K,Ishimaru F,Yoshino T,Niiya K,Harada M

    更新日期：2001-12-01 00:00:00

  • Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR.

    abstract：:A.R.R.O.W. evaluated the superiority of once-weekly carfilzomib plus dexamethasone (Kd) 20/70 mg/m2 vs. twice-weekly Kd 20/27 mg/m2 based on progression-free survival (PFS) in relapsed and/or refractory multiple myeloma patients. Forty Japanese patients (once-weekly arm, n = 26; twice-weekly arm, n = 14) were randomiz...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-020-03013-6

    authors： Takezako N,Shibayama H,Handa H,Hagiwara S,Ozaki S,Suzuki K,Kosugi H,Ri M,Sugiura I,Choi I,Miyamoto T,Iida S

    更新日期：2020-10-10 00:00:00

  • Elevated serum levels of eosinophil major basic protein in patients with myeloproliferative disorders without eosinophilia.

    abstract：:The 12- to 14-kDa eosinophil major basic protein (MBP) is primarily translated as 25-kDa pro-MBP. HL-60, a promyelocytic leukemia cell line, produces pro-MBP but not MBP, suggesting production of pro-MBP by immature granulocytes. We measured the serum levels of total MBP, using an ELISA that detects both pro-MBP and M...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1016/s0925-5710(97)00588-4

    authors： Mukai HY,Ninomiya H,Nagasawa T,Abe T

    更新日期：1997-08-01 00:00:00

  • Recurrent intramural hematoma of the small intestine in a severe hemophilia A patient with a high titer of factor VIII inhibitor: a case report and review of the literature.

    abstract：:A 17-year-old man with severe hemophilia A (factor VIII <1%) developed intermittent left upper quadrant pain. He had a high titer of factor VIII inhibitor (1024 Bethesda units/mL) and was diagnosed with intramural hematoma of the jejunum. He was managed conservatively with activated prothrombin complex concentrate (AP...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1532/IJH97.06053

    authors： Katsumi A,Matsushita T,Hirashima K,Iwasaki T,Adachi T,Yamamoto K,Kojima T,Takamatsu J,Saito H,Naoe T

    更新日期：2006-08-01 00:00:00

  • A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement.

    abstract：:Philadelphia (Ph) chromosome as a result of t (9; 22) (q34; q11) is observed in more than 90% of chromic myeloid leukemia (CML) patients. Cases in which the typical Ph chromosome is not visible at the karyotype level comprise 5-10% of CML patients. CML cases with fusion transcripts such as e13a3 in which ABL exon 3 ra...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-009-0368-4

    authors： Masuko M,Furukawa T,Abe T,Wada R,Maruyama S,Kitajima T,Shibasaki Y,Toba K,Okada M,Aizawa Y

    更新日期：2009-09-01 00:00:00

  • Somatic thrombopoietin (THPO) gene mutations in childhood myeloid leukemias.

    abstract：:We report, for the first time, a non-syndromic infant with a reversible myeloproliferative disease that harbors a germline hereditary thrombopoietin (THPO) gene mutation, a condition that is known to induce familial thrombocytosis at increasing age. In order to investigate whether somatic THPO gene mutations play a ro...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-015-1759-3

    authors： Houwing ME,Koopman-Coenen EA,Kersseboom R,Gooskens S,Appel IM,Arentsen-Peters ST,de Vries AC,Reinhardt D,Stary J,Baruchel A,de Haas V,Blink M,Lopes Cardozo RH,Pieters R,Michel Zwaan C,van den Heuvel-Eibrink MM

    更新日期：2015-07-01 00:00:00

  • Prognostic value of early response to treatment combined with conventional risk factors in pediatric acute lymphoblastic leukemia.

    abstract：:To determine useful prognostic factors in treating childhood acute lymphoblastic leukemia (ALL), we correlated conventional risk factors and bone marrow response 14 days after induction chemotherapy. Our study included 116 precursor B-cell (n = 104) and T-cell (n = 12) ALL patients treated with our protocol between 19...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1532/ijh97.04114

    authors： Morimoto A,Kuriyama K,Hibi S,Todo S,Yoshihara T,Kuroda H,Imashuku S

    更新日期：2005-04-01 00:00:00

  • Early lymphocyte recovery predicts clinical outcome after HSCT with mycophenolate mofetil prophylaxis in the Japanese population.

    abstract：:Immune reconstitution affects clinical outcomes after allogeneic hematopoietic stem cell transplantation (HSCT), and it has been suggested that lymphocyte recovery affects survival after HSCT. However, few studies have examined lymphocyte recovery in Asian patients who received mycophenolate mofetil (MMF) prophylaxis ...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-018-2437-z

    authors： Kurata K,Yakushijin K,Mizuno I,Gomyo H,Okamura A,Ichikawa H,Sakai R,Mizutani Y,Kakiuchi S,Miyata Y,Kitao A,Sanada Y,Inui Y,Uryu K,Kawamoto S,Sugimoto T,Yamamoto K,Ito M,Matsuoka H,Murayama T,Minami H

    更新日期：2018-07-01 00:00:00

  • Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?

    abstract：:The life expectancy of thalassemic patients has increased, and now approaches that of healthy individuals, thanks to improved treatment regimens. However, pregnancy in women with β-Thalassemia Μajor remains a challenging condition. Recent advances in managing this haemoglobinopathy offer the potential for safe pregnan...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-016-1945-y

    authors： Diamantidis MD,Neokleous N,Agapidou A,Vetsiou E,Manafas A,Fotiou P,Vlachaki E

    更新日期：2016-05-01 00:00:00

  • Monosomies 7p and 12p and FLT3 internal tandem duplication: possible markers for diagnosis of T/myeloid biphenotypic acute leukemia and its clonal evolution.

    abstract：:Biphenotypic acute leukemia co-expressing T-lymphoid and myeloid markers is rare, accounting for less than 1% of acute leukemias. However, several clinical characteristics including male predominance, frequent lymphadenopathy and unfavorable outcome have been identified. Recurrence of monosomies 7p and/or 12p in T/mye...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-009-0268-7

    authors： Matsumoto Y,Taki T,Fujimoto Y,Taniguchi K,Shimizu D,Shimura K,Uchiyama H,Kuroda J,Nomura K,Inaba T,Shimazaki C,Horiike S,Taniwaki M

    更新日期：2009-04-01 00:00:00

  • Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles.

    abstract：:Recent evidence suggests that mesenchymal stem cells (MSC) selectively home to tumors, where they contribute to the formation of tumor-associated stroma. This effect can be opposed by genetically modifying MSC to produce high levels of anti-cancer agents that blunt tumor growth kinetics and inhibit the growth of tumor...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：10.1532/IJH97.06230

    authors： Hall B,Dembinski J,Sasser AK,Studeny M,Andreeff M,Marini F

    更新日期：2007-07-01 00:00:00

  • Significance of immature platelet fraction and CD41-positive cells at birth in early onset neonatal thrombocytopenia.

    abstract：:Early thrombocytopenia is a common hematological abnormality in sick neonates. Here, we examined the relationship between early thrombocytopenia in neonates and parameters associated with thrombopoiesis to identify predictive factors at birth. Two hundred and forty-four neonates admitted to the neonatal intensive care...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-009-0482-3

    authors： Kihara H,Ohno N,Karakawa S,Mizoguchi Y,Fukuhara R,Hayashidani M,Nomura S,Nakamura K,Kobayashi M

    更新日期：2010-03-01 00:00:00

  • Evi-1 as a critical regulator of leukemic cells.

    abstract：:Ecotropic viral integration site-1 (EVI-1) has been recognized as one of the dominant oncogenes associated with murine and human myeloid leukemia. Recent clinical studies demonstrated that high EVI-1 expression was an independent negative prognostic indicator of survival in leukemia patients. In addition, gene-targeti...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：10.1007/s12185-010-0618-5

    authors： Goyama S,Kurokawa M

    更新日期：2010-06-01 00:00:00

  • Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan.

    abstract：:We performed a retrospective population-based cohort study of acute myeloid leukemia (AML) in Miyazaki Prefecture, Japan. Over 6 years, we diagnosed 221 patients (211 adults and 10 children) with AML, indicating an incidence of AML in Miyazaki Prefecture of 3.2 per 100,000 per year. In 193 adult patients with non-acut...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-012-1146-2

    authors： Matsunaga T,Yamashita K,Kubuki Y,Toyama T,Imataki O,Maeda K,Kawano N,Satou S,Kawano H,Ishizaki J,Yoshida S,Kameda T,Sasaki T,Sekine M,Kamiunten A,Taniguchi Y,Hidaka T,Katayose K,K-Shimoda H,Shide K,Yamamoto S,Mo

    更新日期：2012-09-01 00:00:00

  • The myelodysplastic syndromes: morphology, risk assessment, and clinical management (2002).

    abstract：:The Myelodysplastic Syndromes (MDS) represent a group of potentially acute myeloid leukemic disorders. There exists a delicate balance between increased apoptosis and proliferation of the leukemic hematopoietic stem cell that permits many patients to survive for years. When the balance shifts towards proliferation AML...

    journal_title：International journal of hematology

    pub_type： 杂志文章,评审

    doi：10.1007/BF03165122

    authors： Bennett JM,Kouides PA,Forman SJ

    更新日期：2002-08-01 00:00:00

  • Identification of amino acid residues responsible for von Willebrand factor binding to sulfatide by charged-to-alanine-scanning mutagenesis.

    abstract：:von Willebrand factor (VWF) performs its hemostatic functions through binding to various proteins. The A1 domain of VWF contains binding sites of not only physiologically important ligands, but also exogenous modulators that induce VWF-platelet aggregation. Sulfatides, 3-sulfated galactosyl ceramides, that are express...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-008-0065-8

    authors： Nakayama T,Matsushita T,Yamamoto K,Mutsuga N,Kojima T,Katsumi A,Nakao N,Sadler JE,Naoe T,Saito H

    更新日期：2008-05-01 00:00:00

  • Two cases showing clonal progression with full evolution from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome to myelodysplastic syndromes and leukemia.

    abstract：:We report 2 paroxysmal nocturnal hemoglobinuria (PNH) patients who were initially diagnosed with aplastic anemia and sequentially developed PNH, myelodysplastic syndromes (MDS), and leukemia. Flow cytometry and cytogenetic analysis showed the initial appearance and expansion of PNH clones, gradual replacement of PNH c...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：

    authors： Ishihara S,Nakakuma H,Kawaguchi T,Nagakura S,Horikawa K,Hidaka M,Asou N,Mitsuya H

    更新日期：2000-08-01 00:00:00

  • Molecular analysis of afibrinogenemic mutations caused by a homozygous FGA1238 bp deletion, and a compound heterozygous FGA1238 bp deletion and novel FGA c.54+3A>C substitution.

    abstract：:We identified two afibrinogenemic girls in two Japanese families and performed molecular analysis to clarify the mechanisms of fibrinogen defects. Genetic analyses were performed by PCR amplification of the fibrinogen gene and DNA sequence analysis. To analyze the mechanisms of mature fibrinogen defects in plasma, we ...

    journal_title：International journal of hematology

    pub_type： 杂志文章

    doi：10.1007/s12185-012-1100-3

    authors： Takezawa Y,Terasawa F,Matsuda K,Sugano M,Tanaka A,Fujiwara M,Kainuma K,Okumura N

    更新日期：2012-07-01 00:00:00